Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  leflunomide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.035, CDR0000067275, SUGEN-990711, NCT00004071
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.015, CDR0000066226, MSKCC-98020, UCLA-HSPC-980105201, NCT00003293
Phase I/II Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) in Ovarian Cancer, non-Small Cell Lung Cancer, and Prostate Cancer (Summary Last Modified 07/97)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.004, NCI-V96-1091
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-088, NCT01611675
Phase II Study of Leflunomide (SU101) in Patients with Recurrent Stage III or IV Ovarian Cancer (Summary Last Modified 11/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.009, NYU-9828
Phase II Study of Leflunomide (SU101) in Patients with Advanced Non-Small Cell Lung Cancer (Summary Last Modified 09/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.010
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.021, CDR0000066904, MSKCC-98111, NCI-G99-1506, NCT00003775
Phase I Study of SU101 Administered by Four Weekly 24-Hour Infusions for Recurrent Malignant Gliomas (Summary Last Modified 07/97)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-95019, NCI-V95-0663
Phase I Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) in Advanced Solid Malignancies (Summary Last Modified 08/97)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.002, NCI-V96-1090
Phase I Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) Given Weekly Following a Loading Dose in Advanced Solid Malignancies (Summary Last Modified 12/97)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SUGEN-SU101.003, NCI-V96-1092
Phase I Study of Leflunomide (SU101) in Pediatric Patients with Refractory Malignancy (Summary Last Modified 08/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 3 to 21
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-97-C-0087E, SUGEN-NCI-97-C-0087
Phase I Study of Leflunomide (SU101) and Mitoxantrone in Patients with Stage IV Hormone Refractory Prostate Cancer (Summary Last Modified 04/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-HSPC-980901101B, SUGEN-SU101.032A, NCI-G99-1550
Start Over